

Effect of rosiglitazone, compared to sulphonylurea, on endothelial function in Chinese patients with type two diabetes

Submission date

14/11/2006

Recruitment status

No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date

29/11/2006

Overall study status

Completed

☐ Statistical analysis plan

☒ Results

Last Edited

20/11/2007

Condition category

Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Karen Lam

Contact details

The University of Hong Kong

Queen Mary Hospital

Pokfulam

Hong Kong

-

Additional identifiers

Protocol serial number

HKCTR-1

Study information

Scientific Title**Study objectives**

1. Rosiglitazone improves endothelial function independent of its effect on glycemic control
2. Rosiglitazone affects soluble receptor of advanced glycation end products independent of its effect on glycemic control

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Institutional Review Board of the University of Hong Kong /Hospital Authority Hong Kong West Cluster on the 19th March 2004 (ref: UW 04-045 T/367).

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Type two diabetes

Interventions

Patients were randomised to receive add-on therapy with either rosiglitazone 4 mg or glibenclamide 5 mg (or gliclazide 80 mg) daily while keeping the doses of their usual anti-diabetic agents constant. After four weeks, the doses of the add-on therapy were doubled in subjects with fasting blood glucose level greater than 8.0 mmol/l and without symptomatic or asymptomatic hypoglycemia defined as blood glucose level less than 3.0 mmol/l. The dosages of all anti-diabetic agents were then kept constant for another 20 weeks.

There was no washout period and all study medications were administered orally.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Rosiglitazone and sulphonylurea

Primary outcome(s)

Changes in endothelial function in patients with type two diabetes

Key secondary outcome(s))

1. Changes in blood pressure and metabolic parameters such as C-reactive protein.
2. Changes in serum soluble Receptor for Advanced Glycation End products (sRAGE) and advanced glycation end products.

Completion date

Eligibility

Key inclusion criteria

1. Chinese men and women aged 30 to 70 years
2. Type two diabetes (defined by the World Health Organization [WHO] criteria) diagnosed after 30 years of age
3. On diet with/without sulphonylurea (less than or equal to half-maximum dose) with/without metformin for at least six months
4. No change in anti-diabetic, lipid lowering and anti-hypertensive in preceding 12 weeks
5. Body Mass Index (BMI) more than or equal to 23 and less than or equal to 35 kg/m²
6. Systolic blood pressure less than or equal to 160 mmHg and diastolic blood pressure less than or equal to 90 mmHg
7. HbA1c levels between 7.5 and 10.5% inclusively (normal less than or equal to 6.1%) on at least two occasions in the past three months
8. Female patients must be post-menopausal (i.e. more than six months without menstrual period), surgically sterilised, or using hormonal contraceptives or intrauterine devices

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Pregnancy or lactation
2. Any clinically significant abnormality identified on the screening physical examination, laboratory tests, or electrocardiogram which, in the judgement of the investigator, would preclude the safe completion of the study
3. Use of anti-diabetic drugs other than metformin or sulphonylurea within 12 weeks
4. Use of any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication
5. Patients with a documented history of significant hypersensitivity to any drugs including thiazolidinedione and sulphonylurea (e.g., difficulty in swallowing or breathing, or tachycardia)
6. Active alcohol or drug abuse within the last six months
7. Presence of clinically significant renal or hepatic disease:
 - 7.1. Serum creatinine above Upper Normal Range (UNR) (creatinine more than 128 umol/L for males and more than 107 umol/L for females)
 - 7.2. Proteinuria more than 1 gm/day
 - 7.3. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin, or alkaline phosphatase more than two times above UNR
8. Significant anaemia (haemoglobin less than 11 g/dl for males or less than 10 g/dl for females)
9. Patients with haemoglobinopathies
10. Leukocyte count less than $3.0 \times 10^9/L$ or platelet count less than $120 \times 10^9/L$

11. Patients with severe angina, coronary insufficiency, heart failure (New York Heart Association [NYHA] class III or IV), or history of cardiovascular event in the past six months
12. Patients with electrocardiographic evidence of left ventricular hypertrophy based upon the maximal voltage of Sv1 plus the maximal voltage of Rv5 or Rv6 more than 3.5 mV and ST-T segment changes
13. Symptomatic diabetic neuropathy of sufficient severity to require treatment for control of symptoms (e.g. painful peripheral neuropathy, symptomatic orthostatic hypotension, urinary retention, pedal ulcers, gastric stasis, etc.)
14. Patients with history of psychiatric illness

Date of first enrolment

23/03/2004

Date of final enrolment

01/04/2006

Locations

Countries of recruitment

Hong Kong

Study participating centre

The University of Hong Kong

Pokfulam

Hong Kong

-

Sponsor information

Organisation

Hong Kong University Research Committee (Hong Kong)

ROR

<https://ror.org/02zhqgq86>

Funder(s)

Funder type

University/education

Funder Name

Hong Kong University Research Committee (Hong Kong) (project no. HKU 7637/05M)

Funder Name

HK Innovation and Technology Support Programme (Hong Kong) (project no. ITS/048/03)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/09/2007		Yes	No